Boehringer Ingelheim Drug Pipeline

Boehringer Ingelheim maintains a substantial clinical development portfolio, with 84 active trials out of 1170 total registered since 2008. These active trials span from Phase 1 through Phase 4, with the largest number currently in Phase 1. The company’s research activity extends across 12 therapeutic areas, though a significant portion is concentrated in oncology, which accounts for 54% of active programs. Within oncology, the most active indications are advanced solid tumors and small cell lung cancer (SCLC), followed by head and neck cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. While several oncology programs are in early phases, one Phase 3 trial is ongoing in SCLC and another in NSCLC. Beyond oncology, other key therapeutic areas include metabolic diseases, respiratory diseases, cardiovascular diseases, immunology, and central nervous system disorders, each with a smaller number of active trials. This distribution indicates a strategic emphasis on oncology, alongside continued investment in a diverse range of other therapeutic areas.